Drug Patents owned by Sun Pharm
1. List of Absorica Ld drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9750711 | SUN PHARM | Low dose oral pharmaceutical composition of isotretinoin |
May, 2035
(11 years from now) | |
| US9700535 | SUN PHARM | Oral pharmaceutical composition of isotretinoin |
Aug, 2035
(12 years from now) | |
Drugs and Companies using ISOTRETINOIN ingredient
Market Authorisation Date: 05 November, 2019
Treatment: NA
Dosage: CAPSULE;ORAL
2. List of Bromsite drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8778999 | SUN PHARM | Non-steroidal anti-inflammatory ophthalmic compositions |
Aug, 2029
(6 years from now) | |
Drugs and Companies using BROMFENAC SODIUM ingredient
Market Authorisation Date: 08 April, 2016
Treatment: Treatment of postoperative inflammation and prevention of ocular pain in patients undergoing cataract surgery
Dosage: SOLUTION/DROPS;OPHTHALMIC
3. List of Cequa drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8980839 | SUN PHARM | Topical aqueous nanomicellar, ophthalmic solutions and uses thereof |
Aug, 2033
(10 years from now) | |
| US10441630 | SUN PHARM | Topical formulations and uses thereof |
Aug, 2033
(10 years from now) | |
| US9937225 | SUN PHARM | Topical formulations and uses thereof |
Aug, 2033
(10 years from now) | |
| US10918694 | SUN PHARM | Topical cyclosporine-containing formulations and uses thereof |
Feb, 2037
(13 years from now) | |
Drugs and Companies using CYCLOSPORINE ingredient
Market Authorisation Date: 14 August, 2018
Treatment: Increase tear production in patients with keratoconjunctivitis sicca (dry eye).
Dosage: SOLUTION;OPHTHALMIC
4. List of Drizalma Sprinkle drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10413525 | SUN PHARM | Duloxetine sprinkles |
Apr, 2037
(13 years from now) | |
| US11202772 | SUN PHARM | Duloxetine sprinkles |
Apr, 2037
(13 years from now) | |
| US10959982 | SUN PHARM | Duloxetine sprinkles |
Apr, 2037
(13 years from now) | |
| US9839626 | SUN PHARM | Duloxetine sprinkles |
Apr, 2037
(13 years from now) | |
Drugs and Companies using DULOXETINE HYDROCHLORIDE ingredient
Market Authorisation Date: 19 July, 2019
Treatment: NA
Dosage: CAPSULE, DELAYED REL PELLETS;ORAL
5. List of Ezallor Sprinkle drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10413543 | SUN PHARM | Stable multiparticulate pharmaceutical composition of rosuvastatin |
Feb, 2036
(12 years from now) | |
Drugs and Companies using ROSUVASTATIN CALCIUM ingredient
Market Authorisation Date: 18 December, 2018
Treatment: NA
Dosage: CAPSULE;ORAL
6. List of Infugem drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9241948 | SUN PHARM | Ready to be infused gemcetabine solution |
Jul, 2033
(10 years from now) | |
Drugs and Companies using GEMCITABINE HYDROCHLORIDE ingredient
Market Authorisation Date: 16 July, 2018
Treatment: NA
Dosage: SOLUTION;INTRAVENOUS
7. List of Odomzo drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US8178563 | SUN PHARM | Compounds and compositions as hedgehog pathway modulators |
Jul, 2029
(6 years from now) | |
| US8063043 | SUN PHARM | Salts of N-[6-cis-2,6-dimethylmorpholin-4-yl)pyridine-3-yl]-2-methyl-4′-(trifluoromethoxy)[1,1′-biphenyl]-3-carboxamide |
Sep, 2029
(6 years from now) | |
| US10266523 | SUN PHARM | Crystaline forms of N-[6-(cis-2,6-dimethylmorpholine-4-yl)pyridine-3-yl]-2-Methyl-4′-(trifluoromethoxy) [1,1′-biphenyl]-3-Methanamide monophosphate, and process of preparation thereof |
Mar, 2036
(12 years from now) | |
Drugs and Companies using SONIDEGIB PHOSPHATE ingredient
Market Authorisation Date: 24 July, 2015
Treatment: Treatment of basal cell carcinoma
Dosage: CAPSULE;ORAL
ODOMZO family patents
14
United States
6
China
4
Japan
4
Argentina
4
European Union
3
Poland
3
Korea, Republic of
3
Brazil
3
Spain
3
Norway
3
Portugal
2
Chile
2
Peru
2
Georgia
2
Canada
2
Slovenia
2
Cuba
2
Ukraine
2
El Salvador
2
Hong Kong
2
Costa Rica
2
Taiwan
2
Morocco
2
Honduras
2
Cyprus
2
Denmark
2
Mexico
2
New Zealand
2
EA
2
Australia
2
San Marino
2
South Africa
2
Ecuador
2
Tunisia
2
Israel
2
Jordan
2
Malaysia
1
ME
1
Dominican Republic
1
Luxembourg
1
Lithuania
1
Netherlands
1
Croatia
1
Guatemala
1
Hungary
1
Nicaragua
1
Colombia
1
Russia
1
Singapore
8. List of Riomet Er drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9962336 | SUN PHARM | Extended release suspension compositions |
May, 2035
(11 years from now) | |
Drugs and Companies using METFORMIN HYDROCHLORIDE ingredient
Market Authorisation Date: 29 August, 2019
Treatment: NA
Dosage: FOR SUSPENSION, EXTENDED RELEASE;ORAL
9. List of Winlevi drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8865690 | SUN PHARM | 17alfa, 21-dihydroxypregnene esters as antiandrogenic agents |
Jul, 2023
(a month from now) | |
| US9211295 | SUN PHARM | 17 alpha, 21-dihydroxypregnene esters as antiandrogenic agents |
Jul, 2023
(a month from now) | |
| US8143240 | SUN PHARM | 17α, 21-dihydroxypregnene esters as antiandrogenic agents |
Jan, 2024
(7 months from now) | |
| US9486458 | SUN PHARM | Enzymatic process for obtaining 17 alpha-monoesters of cortexolone and/or its 9,11-dehydroderivatives |
Jul, 2028
(5 years from now) | |
| US10159682 | SUN PHARM | Enzymatic process for obtaining 17 alpha-monoesters of cortexolone and/or its 9,11-dehydroderivatives |
Aug, 2028
(5 years from now) | |
| US11207332 | SUN PHARM | Enzymatic process for obtaining 17 α-monoesters of cortexolone and/or its 9,11-dehydroderivatives |
Nov, 2028
(5 years from now) | |
| US9433628 | SUN PHARM | Enzymatic process for obtaining 17α-monoesters of cortexolone and/or its 9,11-dehydroderivatives |
Feb, 2029
(5 years from now) | |
| US8785427 | SUN PHARM | Enzymatic process for obtaining 17 alpha-monoesters of cortexolone and/or its 9,11-dehydroderivatives |
Jul, 2030
(7 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity (NCE) | Aug 26, 2025 |
Drugs and Companies using CLASCOTERONE ingredient
NCE-1 date: 2024-08-26
Market Authorisation Date: 26 August, 2020
Treatment: Method of treating acne vulgaris with topically applied cortexolone 17a-propionate; Method of treating acne vulgaris with topically applied cortexolone 17alpha-propionate
Dosage: CREAM;TOPICAL
WINLEVI family patents
15
United States
8
European Union
5
Denmark
5
Spain
5
Mexico
5
Portugal
4
Poland
4
Canada
4
Slovenia
4
China
4
RS
4
Japan
4
Croatia
3
Hungary
3
Argentina
3
New Zealand
2
Korea, Republic of
2
Australia
2
Italy
2
South Africa
2
Russia
1
Brazil
1
Turkey
1
Lithuania
1
Germany
1
Austria
10. List of Xelpros drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9539262 | SUN PHARM | Ophthalmic composition comprising a prostaglandin |
Oct, 2028
(5 years from now) | |
| US9629852 | SUN PHARM | Ophthalmic composition comprising a prostaglandin |
Sep, 2029
(6 years from now) | |
Drugs and Companies using LATANOPROST ingredient
Market Authorisation Date: 12 September, 2018
Treatment: Reducing elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension
Dosage: EMULSION;OPHTHALMIC
11. List of Yonsa drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9889144 | SUN PHARM | Abiraterone acetate formulation and methods of use |
Mar, 2034
(10 years from now) | |
| US10292990 | SUN PHARM | Abiraterone steroid formulation |
May, 2034
(10 years from now) | |
Drugs and Companies using ABIRATERONE ACETATE ingredient
Market Authorisation Date: 22 May, 2018
Treatment: Use in combination with methylprednisolone for the treatment of patients with prostate cancer
Dosage: TABLET;ORAL
YONSA family patents
14
United States
4
Korea, Republic of
4
Japan
3
China
3
Australia
3
Singapore
3
European Union
2
Canada
2
Brazil
2
Hong Kong
2
Taiwan
2
Morocco
2
Mexico
2
Tunisia
2
Israel
1
Chile
1
Poland
1
Philippines
1
Argentina
1
Spain
1
New Zealand
1
EA
1
Colombia
1
South Africa
1
Moldova, Republic of
1
Russia
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic